



Summit Therapeutics plc
(‘Summit’ or the ‘Company’)

Summit Therapeutics to Present at the Canaccord Genuity Growth Conference

Oxford, UK, and Cambridge, MA, US, 1 August 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces that Mr Glyn Edwards, Chief Executive Officer, will present at the Canaccord Genuity Growth Conference on 8 August 2019 at 8:00am EDT in Boston.

A live webcast of the presentation will be available in the Investors section of the Company's website, www.summitplc.com. A replay of the webcast will be available from the same location soon after the live presentation.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by *C. difficile*, *N. gonorrhoeae* and Enterobacteriaceae and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit

Glyn Edwards / Richard Pye (UK office)
Michelle Avery (US office)

Tel: 44 (0)1235 443 951
+1 617 225 4455

Cairn Financial Advisers LLP (Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7213 0880

N+1 Singer (Joint Broker)
Aubrey Powell / Jen Boorer, Corporate Finance
Tom Salvesen, Corporate Broking

Tel: +44 (0)20 7496 3000

Bryan Garnier & Co Limited (Joint Broker)
Phil Walker / Dominic Wilson

Tel: +44 (0)20 7332 2500

MSL Group (US)
Jon Siegal

Tel: +1 781 684 6557
summit@mslgroup.com

Consilium Strategic Communications (UK)
Mary-Jane Elliott / Sue Stuart / Sukaina Virji
Lindsey Neville

Tel: +44 (0)20 3709 5700
summit@consilium-comms.com

-END-